NASDAQ:CLSN - Celsion Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Celsion Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.35 +0.01 (+0.75 %) (As of 02/18/2020 08:06 AM ET) Add Compare Today's Range$1.16Now: $1.35▼$1.3650-Day Range$1.34MA: $1.54▼$1.7252-Week Range$1.05Now: $1.35▼$2.63Volume310,940 shsAverage Volume164,867 shsMarket Capitalization$30.62 millionP/E RatioN/ADividend YieldN/ABeta1.98 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLSN Previous Symbol CUSIPN/A CIK749647 Webhttp://www.celsion.com/ Phone609-896-9100Debt Debt-to-Equity Ratio0.67 Current Ratio2.58 Quick Ratio2.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$500,000.00 Price / Sales61.25 Cash FlowN/A Price / Cash FlowN/A Book Value$1.11 per share Price / Book1.21Profitability EPS (Most Recent Fiscal Year)($0.68) Net Income$-11,880,000.00 Net Margins-1,653.20% Return on Equity-57.46% Return on Assets-24.93%Miscellaneous Employees29 Outstanding Shares22,760,000Market Cap$30.62 million Next Earnings Date4/3/2020 (Estimated) OptionableOptionable Receive CLSN News and Ratings via Email Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CLSN Rates by TradingView Celsion (NASDAQ:CLSN) Frequently Asked Questions What is Celsion's stock symbol? Celsion trades on the NASDAQ under the ticker symbol "CLSN." When did Celsion's stock split? How did Celsion's stock split work? Celsion's stock reverse split on the morning of Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split. How were Celsion's earnings last quarter? Celsion Co. (NASDAQ:CLSN) announced its quarterly earnings results on Friday, November, 15th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.05. The biotechnology company earned $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative return on equity of 57.46% and a negative net margin of 1,653.20%. View Celsion's Earnings History. When is Celsion's next earnings date? Celsion is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Celsion. What is the consensus analysts' recommendation for Celsion? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celsion. Has Celsion been receiving favorable news coverage? Media coverage about CLSN stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Celsion earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Celsion. Who are some of Celsion's key competitors? Some companies that are related to Celsion include Genprex (GNPX), CannTrust (CTST), NeuBase Therapeutics (NBSE), Paratek Pharmaceuticals (PRTK), Otonomy (OTIC), CymaBay Therapeutics (CBAY), Clearside Biomedical (CLSD), ESSA Pharma (EPIX), Cyclerion Therapeutics (CYCN), Aquestive Therapeutics (AQST), REDHILL BIOPHAR/S (RDHL), Xeris Pharmaceuticals (XERS), Millendo Therapeutics (MLND), Zynerba Pharmaceuticals (ZYNE) and IMMUTEP LTD/S (IMMP). What other stocks do shareholders of Celsion own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Agenus (AGEN), Rexahn Pharmaceuticals (REXN), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), NovaBay Pharmaceuticals (NBY), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Novavax (NVAX) and Tesla (TSLA). Who are Celsion's key executives? Celsion's management team includes the folowing people: Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 68)Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 62)Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 59)Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 60)Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 61) Who are Celsion's major shareholders? Celsion's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.35%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper. View Institutional Ownership Trends for Celsion. Which institutional investors are buying Celsion stock? CLSN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper. View Insider Buying and Selling for Celsion. How do I buy shares of Celsion? Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Celsion's stock price today? One share of CLSN stock can currently be purchased for approximately $1.35. How big of a company is Celsion? Celsion has a market capitalization of $30.62 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-11,880,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Celsion employs 29 workers across the globe.View Additional Information About Celsion. What is Celsion's official website? The official website for Celsion is http://www.celsion.com/. How can I contact Celsion? Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected] MarketBeat Community Rating for Celsion (NASDAQ CLSN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 369 (Vote Outperform)Underperform Votes: 291 (Vote Underperform)Total Votes: 660MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe CLSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2020 by MarketBeat.com StaffFeatured Article: What is the outlook for the FAANG stocks?
